Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
February 2003
in “European Urology Supplements”
TLDR Dutasteride reduces DHT more effectively than finasteride.
The document reports on two studies. The first study found that patients with higher baseline PSA or PV are at a higher risk of surgery for BPH. The second study compared the effectiveness of dutasteride and finasteride in reducing DHT production and found that dutasteride was more effective in reducing DHT to a greater extent than finasteride, achieving maximal reduction in a larger proportion of patients.
View this study on sciencedirect.com →
Related
research The clinical applications of five-alpha reductase inhibitors.
Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.